Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters

12 Dec 2022

Abstract excerpt

Tuberculosis (TB) is an infectious disease that occurs globally. Treatment of TB has been hindered by problems with multidrug-resistant strains (MDR-TB). Fluoroquinolones are one of the main drugs used for the treatment of MDR-TB. The success of therapy can be influenced by genetic factors and their impact on pharmacokinetic parameters. This review was conducted by searching the PubMed database with keywords...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics Pharmacokinetics and Efficacy
Share to Drug Transport and Resistance Mechanisms
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36588725
DOI: 10.3389/fphar.2022.1063413

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parametersPMID 36588725Read ↗

Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients.Semantic proximity Read ↗

Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis PatientsSemantic proximity Read ↗

Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.Semantic proximity Read ↗

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicitySemantic proximity Read ↗

Relationship among genetic polymorphism of SLCO1B1, rifampicin exposure and clinical outcomes in patients with active pulmonary tuberculosis.Semantic proximity Read ↗

Genetic polymorphisms and adverse reactions to antituberculosis therapySemantic proximity Read ↗

Genetic Diversity in Drug Transporters: Impact in African PopulationsSemantic proximity Read ↗

Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis.Semantic proximity Read ↗

Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China.Semantic proximity Read ↗

Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic PerspectiveSemantic proximity Read ↗

SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico.Semantic proximity Read ↗

A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.